Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Extracellular target capture
What ifWhat if the first portion captures a soluble extracellular protein for lysosomal degradation?
Claim language“an intracellular target protein”
An antibody fragment captures the soluble protein in the extracellular fluid. A linked mannose-6-phosphate group engages a cell-surface uptake receptor that carries the complex into the endosomal pathway, where the cargo proceeds to the lysosome.
1.2Direct proteasome recruitment
What ifWhat if the second portion binds directly to a proteasome subunit?
Claim language“a ligand that binds to an E3 ubiquitin ligase”
A peptide on the second portion binds an exposed subunit of the 26S proteasome. The first portion holds the target near the proteasome so its ATPase motor can engage an accessible unstructured segment and feed the protein into the catalytic core.
1.3Host and guest assembly
What ifWhat if the first and second portions associate through a noncovalent host and guest pair?
Claim language“covalently coupling the first and second portions”
The first portion carries a cucurbituril host, and the second carries an adamantylammonium guest. The guest sits in the host cavity and holds the two ligand-bearing portions together in solution.
1.4Permanent amide linkage
What ifWhat if a stable amide bond joins the two ligand-bearing portions?
An activated carboxyl group on one portion reacts with a primary amine on the other to form an amide. Flexible spacers on either side of the amide give the ligands room to engage their respective proteins.
1.5Azide and cyclooctyne coupling
What ifWhat if the two precursors carry an azide and a strained cyclooctyne as their coupling groups?
Claim language“a boronic acid derivative and a diol”
The azide adds across the strained carbon–carbon triple bond to form a triazole junction. The reaction joins the two ligand-bearing precursors in solution without a metal catalyst.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Reporter clearance in production cell lines
A boronic acid bearing a fluorescent reporter ligand reacts with a diol bearing an E3 ubiquitin ligase ligand to form a reversible boronic ester dimer. The isolated dimer is added to production cell cultures that express the reporter as a fusion with a candidate protein. Time-lapse fluorescence measurements track the clearance of each fusion, with untreated wells providing the baseline.
Component substitution
Acylhydrazone in the reversible linker
An aromatic aldehyde on the target-binding portion and an acylhydrazide on the ligase-binding portion replace the boronic acid derivative and diol. The aldehyde and acylhydrazide condense to form a reversible acylhydrazone linkage between the two portions. Preparative chromatography separates the dimer from the starting materials, and liquid chromatography with mass spectrometry measures the intact dimer fraction after dilution into assay buffer.
Exchange of precursor functional group placement
A diol-bearing target protein ligand replaces a boronic-acid-bearing target protein ligand, and a boronic-acid-bearing ligase ligand replaces the corresponding diol-bearing ligand. The two precursors react to place the boron atom on the ligase-binding side of the ester and the diol-derived oxygens on the target-binding side. Preparative chromatography isolates the dimer, and separate binding assays measure its association with the target protein and the ligase.
Parameter or scale variation
Microscale reactions across three feed ratios
Three 200-microliter reactions each contain 1 millimolar target-binding precursor and 0.5, 1.0, or 2.0 millimolar ligase-binding precursor. Each precursor carries one of the two complementary groups required for boronic ester formation. Liquid chromatography measures intact dimer and residual precursors in each reaction, and microscale preparative chromatography collects the dimer fraction from each mixture.
Combination with existing systems
Parallel measurement of protein and transcript
A preformed boronic ester dimer is dispensed into matched wells of cultured cells that express a fluorescent intracellular target. A live-cell imaging system records target fluorescence over time in one set of wells. A quantitative reverse transcription assay measures target transcript abundance in the matched wells at the same sampling times.
Automated or data-driven variant
Mass-guided collection of dimer fractions
A liquid handler combines the boronic acid and diol precursors in an array of reaction vials. An automated sampler injects each mixture into a preparative liquid chromatograph connected through a flow splitter to a mass spectrometer. Collection software opens a fraction valve when the expected dimer mass appears in the programmed retention window and records the source vial and collection position.
Specific version of a part
Bromodomain pocket binding
An acetyl-lysine mimetic binds the acetyl-lysine recognition pocket of an intracellular bromodomain. A substituent that projects toward solvent provides an attachment point for the linker.
Hydroxyproline ligase binding
A hydroxyproline-based ligand binds the substrate-recognition pocket of an E3 ubiquitin ligase complex. The linker attaches through a solvent-facing substituent while the hydroxyproline hydroxyl remains available for hydrogen bonding in the pocket.
Cyclic catechol boronic ester
An arylboronic acid on one portion forms a five-membered cyclic ester with a catechol on the other. Hydrolysis regenerates the two groups, and condensation reforms the ester.
Coupling with water removal
Equimolar arylboronic acid and vicinal diol precursors combine in dry acetonitrile. Activated molecular sieves take up water released during condensation and shift the equilibrium toward the dimer.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1a. a first portion comprising a target protein ligand that binds to an intracellular target protein;
The present application provides bifunctional compounds of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 9 (CDK9). the present application also relates to methods for the targeted degradation of CDK9 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to C
A · US 2019/0111143 A1 · abstract
The present application also relates to methods for the targeted degradation of AURK through the use of the compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to AURK which can be utilized in the treatment of disorders modulated by AURK.
B · US 2022/0218831 A1 · abstract
1.2b. a second portion comprising a ligand that binds to an E3 ubiquitin ligase; and
The present application also relates to targeted degradation of proteins through the use of bifunctional compounds, including bifunctional compounds that link an E3 ubiquitin ligase-binding moiety to a ligand that binds the targeted proteins.
A · US 2019/0111143 A1 · ¶ 12
In another aspect, provided herein are methods of targeting proteins for degradation through the use of compounds, including compounds that link an E3 ubiquitin ligase-binding moiety to a ligand that binds the targeted proteins.
B · US 2022/0218831 A1 · ¶ 13
1.3c. a linker portion covalently coupling the first and second portions;
the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and
A · US 2019/0111143 A1 · ¶ 10
the linker is a group that covalently binds to the targeting ligand and the degron;
B · US 2022/0218831 A1 · ¶ 9
1.4wherein the linker portion comprises reversible covalent boronic ester bonds, the method comprising the step of:
1.5i. reacting a first compound comprising the first portion with a second compound comprising the second portion, wherein the first and second compounds further comprise one of and different functional groups selected from a boronic acid derivative and a diol,
1.6ii. isolating, and optionally characterising, the dimer compound.
The salts can be prepared in situ during the final isolation and purification of the compounds of the application, or separately by reacting the free base or acid function with a suitable acid or base.
A · US 2019/0111143 A1 · ¶ 413
An empty cell means only that no passage was reproduced there.
Statements in these documents
Alternative strategies to inhibit cyclin-dependent kinases, such as CDK9, are needed.
A · US 2019/0111143 A1 · ¶ 7
These drug-like molecules offer the possibility of temporal control over protein expression, and could be useful as biochemical reagents for the treatment of diseases.
A · US 2019/0111143 A1 · ¶ 4
Therefore, there remains a need for structurally diverse inhibitors of Aurora kinase activity, particularly ones that are potent and/or selective inhibitors of AURKA and/or AURKB.
B · US 2022/0218831 A1 · ¶ 3
Targeting these proteins for degradation provides numerous advantages over merely inhibiting protein function (e.g., kinase activity).
B · US 2022/0218831 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355325 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355325/, SHA-256 a726141511b0ac88ab576c1a012589a55569d810cf8bb411a7891843844aac8e